Ionis Pharmaceuticals' RNA drug failed a study, while Eli Lilly invested in a spinout from Kura Oncology.
2 reports, 1 independent
Updated Sep 11
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ionis Pharmaceuticals' RNA drug failed a study, while Eli Lilly invested in a spinout from Kura Oncology.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ionis Pharmaceuticals
American pharmaceutical company
-
Eli Lilly and Company
American pharmaceutical company
-
Kura Oncology
company in La Jolla, United States
Nothing else this week.
Related events
- Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- Clinical failure of a product linked to Ionis Pharmaceuticals shifts financial focus onto Spinraza royalties.